HCM HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […] | ||
Sector Update: Healthcare Stocks Edge Higher Late Afternoon Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre | ||
 HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr | ||
 Panmure and Cavendish reiterate buy on Hutchmed after GSK deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to... | ||
 HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday’s 179.5p... | ||
 HUTCHMED shares rise as lung cancer drug trial hits key targets Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in... | ||
HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ... HUTCHMED (China) Ltd (HCM) reports robust China product sales and global expansion, while advancing its novel ATTC pipeline and maintaining a profitable outlook. | ||
 HUTCHMED H1 Earnings Call Highlights HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported results. The company maintained its full-year oncology revenue guidance of $330 million to $415 milli | ||